Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome

2011-02-01

Additional Metadata
Keywords	Clinical outcomes, Multiple myeloma, Relapsed/refractory disease
Persistent URL	doi.org/10.3816/CLML.2011.n.005, hdl.handle.net/1765/82196
Journal	Clinical Lymphoma, Myeloma and Leukemia
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Blade, J., Sonneveld, P., San Miguel, J., Sutherland, H., Hàjek, R., Nagler, A., … Orlowski, R. (2011). Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome. Clinical Lymphoma, Myeloma and Leukemia, 11(1), 44–49. doi:10.3816/CLML.2011.n.005

Publication